A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain Associated With Post-Acute Sequelae of SARS-CoV-2 Infection (PREVAIL)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05472090 |
|
Recruitment Status :
Completed
First Posted : July 25, 2022
Last Update Posted : September 6, 2023
|
Sponsor:
Tonix Pharmaceuticals, Inc.
Information provided by (Responsible Party):
Tonix Pharmaceuticals, Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Completed |
|---|---|
| Actual Primary Completion Date : | July 12, 2023 |
| Actual Study Completion Date : | July 27, 2023 |